Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis

Key Points

• Efgartigimod demonstrates superior value for treating myasthenia gravis compared to alternatives.
• The evaluation scored efgartigimod higher than ravulizumab, zilucoplan, and rozanolixizumab based on informed analysis.
• Multi-criteria decision analysis was used to assess the treatment options in this multidisciplinary evaluation.
• This highlights the potential for efgartigimod to be a leading choice in myasthenia gravis care, warranting further exploration.

Abstract